Free tool
FAERS Monitor: Prepidil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019617 or its brand name (Prepidil, Dinoprostone). Reports on generic versions are filed under their own applications.
Reports
516
Serious
499
97% of reports
Hospitalization
145
Death reported
38
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy118
- exposure during pregnancy56
- maternal exposure during pregnancy45
- off label use35
- premature baby35
- haemoglobin decreased34
- premature delivery32
- white matter lesion30
- hypospadias26
- disseminated intravascular coagulation25
- foetal anaemia24
- small for dates baby24
- neonatal asphyxia23
- uterine tachysystole21
- premature separation of placenta20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 13 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 10 |
| 2011 | 9 |
| 2012 | 10 |
| 2013 | 20 |
| 2014 | 5 |
| 2015 | 8 |
| 2016 | 16 |
| 2017 | 16 |
| 2018 | 37 |
| 2019 | 11 |
| 2020 | 16 |
| 2021 | 49 |
| 2022 | 66 |
| 2023 | 86 |
| 2024 | 47 |
| 2025 | 46 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| foetal anaemiaSignal | 24 | 9151.8 | 5928.4 | 171,968 |
| uterine tachysystoleSignal | 21 | 6910.0 | 4386.7 | 118,220 |
| neonatal asphyxiaSignal | 23 | 1368.0 | 911.1 | 29,091 |
| white matter lesionSignal | 30 | 991.9 | 697.8 | 28,036 |
| premature separation of placentaSignal | 20 | 536.9 | 348.3 | 10,037 |
| hypospadiasSignal | 26 | 516.0 | 353.9 | 12,694 |
| small for dates babySignal | 24 | 198.0 | 133.9 | 4,489 |
| premature deliverySignal | 32 | 82.1 | 58.7 | 2,479 |
| disseminated intravascular coagulationSignal | 25 | 72.5 | 49.5 | 1,691 |
| foetal exposure during pregnancySignal | 118 | 59.3 | 50.6 | 6,716 |
| premature babySignal | 35 | 47.5 | 34.5 | 1,546 |
| exposure during pregnancySignal | 56 | 36.8 | 28.7 | 1,916 |
| maternal exposure during pregnancySignal | 45 | 20.6 | 15.6 | 822 |
| haemoglobin decreasedSignal | 34 | 13.5 | 9.8 | 383 |
| off label use | 35 | 1.6 | 1.2 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.